

Pioneering EV Therapeutics — Creating the Future of Medicine



EXP01-AD

**A Differentiated Skin Barrier–Restoring MSC-EV Candidate for
Atopic Dermatitis**

EXORPHIA, com



EXP01-AD adds a low-dose weekly SC PoC

SC is now the lead route

EXORPHIA develops native and engineered EV therapeutics with patent applications, candidate potency-linked QC markers, and integrated EV manufacturing / CMC/QC capabilities.

What changed in 2026

- New systemic PoC: once-weekly subcutaneous dosing at 1/100 of the respective prior nonclinical dose.
- TEWL improved close to the normal-group range, with significant suppression of inflammatory skin thickening.
- Low-dose topical PoC remains available as a complementary local-treatment option.



Development priority

LEAD

Subcutaneous | once weekly

Systemic treatment candidate; prioritized for the next translational and IND-enabling package.

OPTION

Topical | once daily

Local-treatment option; advancement can be staged with partner strategy and data needs.

Why partner now

Shape the systemic TPP, MoA/target-engagement work, translational biomarkers and IND-enabling plan before these choices are locked.

Partnering opportunity

Global or regional licensing / co-development at the nonclinical stage; topical development may be included as an option.

Low-dose nonclinical PoC demonstrated across both routes

Severe AD mouse-model studies included oral abrocitinib comparator groups.

LEAD

1/100 dose | once weekly SC

68.1%

lower TEWL vs vehicle
at Day 30

- TEWL approached the normal-group range.
- Inflammatory skin thickening was significantly suppressed.
- Demonstrated a trend toward itch reduction.

OPTION

1/100 dose | once daily topical

25°C / 2 months

stored test article

- TEWL approached the normal-group range.
- Total clinical score AUC significantly improved vs vehicle.
- Demonstrated a trend toward itch reduction.

Exploratory tolerability:

No clear body-weight loss or thymus-weight reduction under the evaluated conditions.

Next de-risking work

MoA / target engagement | skin distribution | human translatability and biomarkers | development candidate / IND-enabling package

Nonclinical results only. Clinical efficacy and safety have not been established. TEWL: transepidermal water loss.